Discontinued — last reported Q1 '21
An increase indicates a deterioration in the long-term commercial outlook for the product, while a decrease suggests stable or improving asset valuation.
This metric represents the non-cash expense recognized when the carrying value of intangible assets associated with a sp...
Peers in the biotechnology sector often report similar impairment charges when specific pipeline assets or marketed drugs face significant market or regulatory headwinds.
uthr_segment_trevyent_intangible_asset_impairment_charges